FDA Awards Second Orphan Drug Designation to Zymeworks for ZW25 in Gastric Cancer

Canada–based, Zymeworks received orphan drug designation from the FDA for its drug candidate, ZW25, for the treatment of gastric cancer, including cancer of the gastro-esophageal junction.

ZW25 is an antibody intended as a treatment option for patients with any solid tumor that expresses the protein human epidermal growth factor receptor 2 (HER2).